Suven Life Sciences has received total 7 product patents from India, Canada, Japan and Eurasia for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2023, 2024 and 2025.
The company received two patents from Canada (CA 2,618,636 & CA 2,626,646), three from India (243298, 244912, 246200) and each one from Japan (4571507) and Eurasia (1494). The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder, (ADHD), Huntington's disease, Parkinson and schizophrenia.
With these new patents, Suven has a total of five granted patents from Canada, 13 from India, 9 from Eurasia and 4 from Japan for the NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
Venkat Jasti, CEO, said, “WE are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally.”
The company has 12 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidates SUVN-502 for Alzheimer's disease and schizophrenia.